Get the Stockscreener App
17.11
0.64%
-0.11
Pre-market:
16.86
-0.25
-1.46%
Delcath Systems Inc stock is traded at $17.11, with a volume of 772.67K.
It is down -0.64% in the last 24 hours and up +31.51% over the past month.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$17.22
Open:
$17.1
24h Volume:
772.67K
Relative Volume:
1.38
Market Cap:
$593.70M
Revenue:
$90.44M
Net Income/Loss:
$561.00K
P/E Ratio:
2,851.67
EPS:
0.006
Net Cash Flow:
$19.19M
1W Performance:
+35.47%
1M Performance:
+31.51%
6M Performance:
+87.61%
1Y Performance:
+57.26%
1-Day Range:
$16.63
$17.28
1-Week Range:
$14.00
$17.42
52-Week Range:
$8.12
$17.42
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
17.11 | 597.51M | 90.44M | 561.00K | 19.19M | 0.006 |
ABT
Abbott Laboratories
|
110.91 | 189.86B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
347.21 | 133.54B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.76 | 116.07B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.42 | 74.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
93.05 | 53.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Renaissance Technologies LLC Trims Position in Delcath Systems, Inc. $DCTH - marketbeat.com
Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Zacks Research - marketbeat.com
Delcath Systems (NASDAQ:DCTH) Hits New 12-Month HighHere's What Happened - marketbeat.com
Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy - Yahoo Finance
Does Delcath Systems (DCTH) Have the Potential to Rally 42.77% as Wall Street Analysts Expect? - Zacks Investment Research
HC Wainwright Boosts Earnings Estimates for Delcath Systems - marketbeat.com
Delcath Systems resumes post-earnings momentum with 10% rally, sets new high (DCTH:NASDAQ) - Seeking Alpha
Delcath Systems (NASDAQ:DCTH) Trading 9.3% HigherStill a Buy? - marketbeat.com
Why Are Delcath Systems, Inc. (NASDAQ:DCTH) Shares at a Fresh Yearly High? - kalkinemedia.com
HC Wainwright Weighs in on Delcath Systems Q1 Earnings - marketbeat.com
Biotech company expanding Washington County HQ - The Business Journals
Delcath Systems Insider Confidence Rewarded, Stock Hits US$536m Market Cap - 富途牛牛
Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
Delcath Systems (NASDAQ:DCTH) Issues Earnings Results, Beats Estimates By $0.16 EPS - marketbeat.com
DCTH Maintained by HC Wainwright & Co. -- Price Target Raised to $32 - GuruFocus
Delcath: Temporary Headwinds Are Fading While Larger Opportunities Approach (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems Inc (DCTH) Stock News Today - TradingKey
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Raises Target Price to $32 - Moomoo
Craig-Hallum Maintains Delcath Systems(DCTH.US) With Buy Rating, Announces Target Price $24 - Moomoo
Delcath Systems, Inc. (DCTH) Stock Analysis: A Promising 52.24% Potential Upside for Healthcare Investors - DirectorsTalk Interviews
Delcath Systems Q2 Revenue Rises to $29.1 Million - Moomoo
Delcath Systems earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Earnings call transcript: Delcath jumps on Q2 2026 revenue beat and raised outlook - Investing.com
Delcath Systems, Inc. Stock 12‑Month Price Target Raised to $24.17, Implies 91% Upside - tradingview.com
Delcath Systems (NASDAQ:DCTH) Price Target Raised to $21.00 at BTIG Research - marketbeat.com
These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months - Yahoo Finance
Delcath Systems Inc (DCTH) Beats Revenue Estimates with $29.1 Mi - GuruFocus
Delcath Systems Announces Q2 2026 Financial Results Highlighting Revenue Growth - kalkinemedia.com
Delcath Systems Up Over 20%, On Pace for Largest Percent Increase Since May 2025 -- Data Talk - Moomoo
Delcath Systems Q2 Earnings Call Highlights - marketbeat.com
Delcath Systems (NASDAQ:DCTH) Sets New 12-Month High After Better-Than-Expected Earnings - marketbeat.com
Delcath Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Delcath Systems Inc reports results for the quarter ended June 30Earnings Summary - tradingview.com
DCTH: Q2 revenue up 21% year-over-year, with raised full-year guidance and expanding clinical reach - TradingView
Delcath Systems, Inc. (DCTH) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Transcript : Delcath Systems, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
DCTH: Q2 2026 revenue grew 21% to $29.1M, with strong HEPZATO sales and steady profitability - tradingview.com
DELCATH SYSTEMS, INC. 1Q 2026: Revenue $29.13M, EPS $0.07— 10-Q Summary - tradingview.com
Delcath Systems (NASDAQ: DCTH) posts Q2 profit and builds oncology pipeline - Stock Titan
Delcath Systems, Inc. Raises Revenue Guidance for the Full Year 2026 - marketscreener.com
Delcath Systems Q2 revenue rises, beats estimates - tradingview.com
Delcath Systems Q2 2026: Revenue $29.1M, Gross Margin 90%, Raises 2026 Guidance to $104M–$108M - tradingview.com
DCTH: Q2 2026 revenue up 20% to $29.1M, with raised full-year guidance and 90% gross margin - tradingview.com
BRIEF-Delcath Systems Q2 Revenue USD 29.133 Million Vs. IBES Estimate USD 26.3 Million - tradingview.com
Press Release: Delcath Systems Reports Second Quarter 2026 Results and Business Highlights - Moomoo
DCTH Looks 66.7% Undervalued on GF Value™ as Growth Momentum Bui - GuruFocus
DCTH Q2'26 Earnings: EPS estimate is (0.09) USD - tradingview.com
DCTH Looks 66.2% Undervalued on GF Value™ - GuruFocus
ClearPoint Neuro, Inc. (CLPT) Options Chain - Yahoo! Finance Canada
Why (DCTH) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):